MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

1.520
+0.010
+0.66%
After Hours: 1.520 0 0.00% 16:00 02/18 EST
OPEN
1.490
PREV CLOSE
1.510
HIGH
1.550
LOW
1.460
VOLUME
735.36K
TURNOVER
--
52 WEEK HIGH
1.730
52 WEEK LOW
0.5339
MARKET CAP
227.68M
P/E (TTM)
-4.1170
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LCTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LCTX News

  • Lineage Cell Therapeutics To Present New Data From OpRegen, Vision Restoration Programs At Association for Research in Vision and Ophthalmology Annual Meeting May 3-7, 2020
  • Benzinga.16h ago
  • Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)
  • Business Wire.16h ago
  • Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference
  • Business Wire.02/10 13:00
  • Lineage Cell Therapeutics Offers Update On Phase I/IIa Study Of OpRegen For Treatment Of Dry Age-Related Macular Degeneration
  • Benzinga.02/06 13:13

More

Industry

Biotechnology & Medical Research
+0.77%
Pharmaceuticals & Medical Research
-0.10%

Hot Stocks

Name
Price
%Change

About LCTX

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
More

Webull offers Lineage Cell Therapeutics Inc (LCTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.